Trial site
The Urology Center of Colorado
Denver, Colorado 80211, United StatesNot linked to an institution yet
- 8running trials
- 4closed trials
The trials here
What the 12 trials at this site are about, from their registry records.
- Phase
- Phase 36 trials
- Phase 23 trials
- Phase 1/21 trial
- Status
- Active, not recruiting8 trials
- Completed3 trials
- Terminated1 trial
- Lead sponsor
- Janssen Research & Development, LLC5 trials
- Pfizer3 trials
- Bayer1 trial
- Epizyme, Inc.1 trial
- Radiation Therapy Oncology Group1 trial
- and 1 more
Running trials
Active, not recruiting
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
NCT04640623· Phase 2· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
NCT04658862· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described
NCT04122976· Bayer· Source
Active, not recruiting
A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
NCT04165317· Phase 3· Pfizer· Source
Active, not recruiting
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
NCT03748641· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT03431350· Phase 2· Janssen Research & Development, LLC· Source
Active, not recruiting
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
NCT03395197· Phase 3· Pfizer· Source
Active, not recruiting
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
NCT02319837· Phase 3· Pfizer· Source
Report an error